A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland

February 13, 2008 updated by: Hospital for Children and Adolescents, Finland

Kallmann Syndrome in Finland

Objective is to characterize epidemiology, clinical and genetic features of Kallmann syndrome in Finland.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

Kallmann syndrome is comprised of idiopathic hypogonadotropic hypogonadism and anosmia (inability to smell). Associated phenotypes may include cryptorchidism, microphallus, bone deformations, mirror movements, hearing loss and infertility. Objective is to characterize epidemiology, clinical and genetic features of Kallmann syndrome in Finland.

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Finland
      • Helsinki, Finland, 00029 HUCH
        • Hospital for Children and Adolescents, Helsinki University Central Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Kallmann syndrome
  • Age 15 yrs or more

Exclusion Criteria:

  • Severe mental retardation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Clinical features including quality of life, reversibility and genetic features of Kallmann syndrome in Finland
Time Frame: 0, 3 mo and during subsequent F/U
0, 3 mo and during subsequent F/U

Secondary Outcome Measures

Outcome Measure
Time Frame
epidemiology
Time Frame: by 2012 (anticipated)
by 2012 (anticipated)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital for Children and Adolescents, Finland

Investigators

  • Study Director: Taneli J Raivio, MD PhD, Hospital for Children and Adolescents, Helsinki University Central Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2007

Primary Completion (Anticipated)

December 1, 2012

Study Completion (Anticipated)

December 1, 2025

Study Registration Dates

First Submitted

January 11, 2008

First Submitted That Met QC Criteria

February 13, 2008

First Posted (Estimate)

February 25, 2008

Study Record Updates

Last Update Posted (Estimate)

February 25, 2008

Last Update Submitted That Met QC Criteria

February 13, 2008

Last Verified

January 1, 2008

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 231408
  • 286/E7/2007

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Kallmann Syndrome

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe